TRYHARD: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb) for Non-HPV Locally Advanced Head and Neck Cancer With Concurrent Chemoradiation
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Jul 2017
At a glance
- Drugs Lapatinib (Primary) ; Cisplatin
- Indications Hypopharyngeal cancer; Laryngeal cancer; Oropharyngeal cancer
- Focus Therapeutic Use
- Acronyms TRYHARD
- 19 Jul 2017 Planned End Date changed from 1 Nov 2018 to 31 Mar 2023.
- 19 Jul 2017 Planned primary completion date changed from 1 Sep 2017 to 31 Mar 2020.
- 19 Jul 2017 Status changed from recruiting to active, no longer recruiting.